相似文献/References:
[1]肖 月,赵 琨,邱英鹏,等.内窥镜手术器械控制系统的应用现状[J].卫生经济研究,2018,(06):3.
[2]隋宾艳,金承刚,邱英鹏,等.内窥镜手术器械控制系统辅助手术成本效果系统评述[J].卫生经济研究,2018,(06):6.
[3]史黎炜,邱英鹏,肖 月,等.内窥镜手术器械控制系统辅助手术的成本测算[J].卫生经济研究,2018,(06):10.
[4]隋宾艳,赵 琨.肝细胞癌患者术后辅助CIK细胞免疫治疗的成本效果分析[J].卫生经济研究,2018,(10):6.
SUI Bin-yan,ZHAO Kun.Cost-effectiveness Analysis of Adjuvant CIK Cell Immunotherapy of Post-operative Patients with Hepatocellular Carcinoma[J].Journal Press of Health Economics Research,2018,(06):6.
[5]李园园,杜灵彬,王悠清,等.浙江省食管癌筛查的经济学评价——以生命年为效果指标[J].卫生经济研究,2022,39(3):18.
LI Yuan-yuan,DU Ling-bin,WANG You-qing,et al.Economic Evaluation of Esophageal Cancer Screening in Zhejiang Province——Take Life Year as the Effect Index[J].Journal Press of Health Economics Research,2022,39(06):18.
[6]姜 巍,刘亭亭,董亚丽,等.“糖尿病诊疗适宜技术培训”策略的成本效果分析[J].卫生经济研究,2022,39(5):21.
JIANG Wei,LIU Ting-ting,DONG Ya-li,et al.Cost-Effectiveness Analysis of Training of Appropriate Technologies for Managing Diabetes[J].Journal Press of Health Economics Research,2022,39(06):21.
[7]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗
晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34.
TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line
Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(06):34.
[8]张良文,张严晖,王晓瑄,等.国产二价HPV疫苗接种的成本效果分析 ——基于Markov模型[J].卫生经济研究,2025,42(11):32.
ZHANG Liangwen,ZHANG Yanhui,WANG Xiaoxuan,et al.Cost-Effectiveness Analysis of Domestically Produced Bivalent HPV Vaccination in China
——Based on a Markov Model[J].Journal Press of Health Economics Research,2025,42(06):32.